Search
for
Sort by
Research 30 of 274
- The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome
- PRIDE Complex (Papulopustules and/or Paronychia, Regulatory Abnormalities of Hair Growth, Itching, Dryness Due to EGFR Inhibitors)
- Dacomitinib-Induced Paronychia Associated With PRIDE Syndrome in a Patient With Non-Small Cell Lung Cancer
- A linear and reticulate crusted keratotic papulopustular eruption: a rare presentation of PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) complex
- Povidone-iodine nail solution is active in treating chemotherapy-associated paronychia
- Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
- Cutaneous Side Effects in Non-Small Cell Lung Cancer Patients Treated with Iressa (ZD1839), an Inhibitor of Epidermal Growth Factor
- Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
- Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
- Dermatological side effects of epidermal growth factor receptor inhibitors: ′Pride′ complex
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Cutaneous side-effects of EGFR inhibitors and their management.
- Alopecia Associated with Indinavir Therapy
- The management of EGFR inhibitor adverse events: a case series and treatment paradigm
- Bacterial Diseases of the Skin
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
- The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
- Cutaneous reactions to targeted therapies in children with CNS tumors: A cross‐sectional study
- Dermatologic Effects of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1: Clinical Challenges and Therapeutic Management
- Erosive pustular dermatosis of the scalp induced by gefitinib: case and review of the literature
- Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
- A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor
- “PRIDE” Complex
- Cutaneous Adverse Events of Targeted Anticancer Therapy: A Review of Common Clinical Manifestations and Management
- Continuous MEK inhibition by AZD6244 (ARRY-142886) results in exhaustion of the cutaneous keratinocytic stem cell pool and resembles senescence driven skin aging
- Targeted Treatments of Non-Small Cell Lung Cancer (NSCLC): Skin Toxicity
- Skin Signs of Zinc Deficiency in Children: A clinical study in Jordan.
- P164 Cutaneous toxicities occurring during amivantamab treatment: the experience of a single large specialist institution
- Pharmacotherapy of plexiform neurofibromas in patients with neurofibromatosis type 1. Possible adverse events and their management
- Acrodermatitis enteropathica – diagnostic challenges